✦ LIBER ✦

Genomic imbalances in ovarian borderline serous and mucinous tumors

✍ Scribed by Jie Hu; Vinish Khanna; Mirka M.W Jones; Urvashi Surti

Book ID: 114135409
Publisher: Elsevier Science
Year: 2002
Tongue: English
Weight: 350 KB
Volume: 139
Category: Article
ISSN: 0165-4608
DOI: 10.1016/s0165-4608(02)00603-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The MRI findings in a case of ovarian mu

The MRI findings in a case of ovarian mucinous borderline tumor mimicking a serous surface borderline tumor

✍ Shimamoto, Aya; Isomoto, Ichiro; Segawa, Keiko; Matsumoto, Ayumi; Abe, Kuniko; U 📂 Article 📅 2014 🏛 Springer 🌐 English ⚖ 968 KB

Serous and mucinous borderline ovarian t

Serous and mucinous borderline ovarian tumors: are there real differences between these two entities?

✍ Virginia Benito; Amina Lubrano; Octavio Arencibia; Norberto Medina; Elisa Álvare 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 158 KB

Genomic aberrations in borderline ovaria

Genomic aberrations in borderline ovarian tumors

✍ Francesca Micci; Lisbeth Haugom; Terje Ahlquist; Hege K Andersen; Vera M Abeler; 📂 Article 📅 2010 🏛 BioMed Central 🌐 English ⚖ 976 KB

Papillary ovarian tumors. Benign tumors

Papillary ovarian tumors. Benign tumors and serous and mucinous cystadenocarcinomas

✍ John J. Malloy; Malcolm B. Dockerty; John S. Welch; Arthur B. Hunt 📂 Article 📅 1966 🏛 American Cancer Society 🌐 English ⚖ 127 KB

Molecular Characterization of 103 Ovaria

Molecular Characterization of 103 Ovarian Serous and Mucinous Tumors

✍ Ildikó Vereczkey; Orsolya Serester; Judit Dobos; Mónika Gallai; Orsolya Szakács; 📂 Article 📅 2010 🏛 Springer Netherlands 🌐 English ⚖ 622 KB

Ovarian serous borderline tumors with in

Ovarian serous borderline tumors with invasive peritoneal implants

✍ David M. Gershenson; Elvio G. Silva; Lawrence Levy; Thomas W. Burke; Judith K. W 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 324 KB 👁 2 views

multivariate regression analyses also were performed. University of Texas M. D. Anderson Cancer Cen-RESULTS. Median follow-up time was 111 months. Four of 7 evaluable patients ter, Houston, Texas. who had second-look surgery (57%) had a response to chemotherapy. Twelve of